Effects of Tinzaparin on Cardio-vascular Outcomes and on Blood Lipids in Diabetic Patients on Chronic Hemodialysis

Diabetes Mellitus Clinical Trial

Official title:

Effects of Tinzaparin Sodium on Cardio-vascular OUtcomes and on Blood Lipids in Diabetic Patients on Chronic HEmodialysis: A Long-term, Prospective Study (The "Tinzaparin COULD HELP" Study).

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT00407641
• Other study ID #: 06_06
• Status: Withdrawn
• Phase: Phase 4
• First received: December 4, 2006
• Last updated: December 21, 2017
• Start date: March 2009
• Est. completion date: January 2017

Study information

• Verified date: January 2017
• Source: Anemia Working Group Romania
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Low molecular weight heparin (LMWH) provides a safe and effective alternative to UFH for hemodialysis anticoagulation. While unfractionated (UF) heparin has been implicated in hyper-lipidemia, the effect of LMWHs on the lipid profile in non-diabetic patients on chronic hemodialysis remains controversial. The effect of LMWH in diabetic patients, a high risk group for developing hyper-lipidemia and cardio-vascular disease, has not been studied.

The study intends to examine the long-term effects of the replacement of UFH by LMWH (tinzaparin sodium) on cardio-vascular outcomes and on lipoprotein profiles in a large group of diabetic patients stable on HD.

Description:

Hemodialysed diabetic patients constitute a high-risk subset of patients for developing cardio-vascular disease, which accounts for nearly 50% of deaths. In those patients, mortality rates probably exceed 20% per year. After stratification for age, race and gender, cardio-vascular mortality is 10-20 times higher in these patients than in the general population. Thus cardio-vascular risk factors in these patients should be managed early, aggressively and in a multi-factorial manner in order to reduce their high cardio-vascular morbidity and mortality.

Low molecular weight heparin (LMWH) provides a safe and effective alternative to UFH for hemodialysis anticoagulation. While unfractionated (UF) heparin has been implicated in hyper-lipidemia, the effect of LMWHs on the lipid profile in non-diabetic patients on chronic hemodialysis remains controversial. The effect of LMWH in diabetic patients, a high risk group for developing hyper-lipidemia and cardio-vascular disease, has not been studied.

The study intends to examine the long-term effects of the replacement of UFH by LMWH (tinzaparin sodium) on cardio-vascular outcomes and on lipoprotein profiles in a large group of diabetic patients stable on HD.

Tinzaparin sodium is superior to UFH in terms of reducing cardio-vascular and cerebrovascular outcomes (primary end-point). Tinzaparin sodium is superior to UFH in terms of reducing the specified lipid parameters of stable diabetic patients on chronic hemodialysis.

A time-to-event analysis is the tool that will be used for recording events rate. Accordingly, the study will aim in enrolling 200 diabetic nephropathy patients, but allowing for a 10% drop-out rate, the number of evaluable patients in the study will be 180.

Therefore, for the primary triple end-point of death/MI/stroke (ischemic) with 180 evaluable patients, we will have an 80% power (at a two-sided alpha level of 0.05) to detect a statistical significant difference in the 2 groups if the rate of events in the UFH group is 30% and on tinzaparin is 13% or less.

For the secondary end-points in cardiovascular morbidity and mortality, if we assume that the event rate in the UFH group is 50%, then a statistical significance can be achieved if the rate in the tinzaparin group is at 30% or less.

For differences in average lipid values between the 2 groups, with 180 evaluable patients, a 2-sided alpha level at 0.05 and with 80% power, we can detect statistical significance if the difference is: for Total Cholesterol=19 mg/dL (SD of 46), for HDL-C = 4.6 mg/dL (SD=11), for TG = 30 mg/dL (SD=72), for LDL-C = 15 (SD=36) and for ApoB = 13 (SD=32).

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: January 2017
• Est. primary completion date: January 2015
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• willingness to give written informed consent for participation in the study

• age 18-80 years old

• ability to understand and follow instructions and able to participate in the study for the entire period

• clinically stable (based on the investigator's judgment) within the three months prior to the screening visit

• written and signed agreement

Exclusion Criteria:

• antecedents of cerebrovascular accident, documented myocardial infarction, coronary angioplasty or bypass surgery within 6 months prior to the screening visit

• currently enrollment in any other investigational device or drug study, or participation in another clinical study within 30 days prior to the screening visit

• known or suspected drug or alcohol abuse

• known congenital or acquired bleeding disorders including hepatic failure and amyloidosis, present active major bleeding;

• increased risk of hemorrhage, due to: pericarditis or bacterial endocarditis, severe uncontrolled hypertension, active ulcerative and angiodysplastic gastrointestinal disease, hemorrhagic stroke, shortly after brain, spinal or ophthalmological surgery, concomitant treatment with platelet inhibitors, recent surgical procedures (especially with hemorrhagic complications or those in which hemorrhagic complications would be very severe - cardio-vascular, ophthalmological or neurological), planned surgical procedure within the next week, (history of) heparin-induced thrombocytopenia, with any other disease which, in the opinion of the investigator, makes unacceptable his/her inclusion in the study (known hypersensitivity to heparin, benzyl alcohol, or pork products that should not be treated with innohep®, severe psychiatric disorders, age <18 years, malignant disorders and a life expectancy <6 months, patients that were involved in another research study (studies) in the last month.

Related Conditions & MeSH terms

• Diabetes Mellitus
• Hemodialysis

Intervention

Drug:
• Tinzaparin administration
Patients will receive tinzaparin during the HD session
• Heparin administration
Patients will receive Heparin as an anticoagulant during the HD session.

Locations

Country	Name	City	State
Romania	Baia Mare County Hospital	Baia Mare
Romania	"Sarah" Hemodialysis Centre	Brasov
Romania	"Dr Carol Davila" Teaching Hospital of Nephrology	Bucharest
Romania	"N Paulescu" Institute	Bucharest
Romania	Fundeni Clinical Hospital	Bucharest
Romania	Cluj University Hospital	Cluj
Romania	Dolj County Hospital	Craiova
Romania	Vrancea County Hospital	Focsani
Romania	"CI Parhon" Clinical Hospital	Iasi
Romania	Bihor County Hospital	Oradea
Romania	Prahova County Hospital	Ploiesti
Romania	Dambovita County Hospital	Targoviste
Romania	Timisoara County Hospital	Timisoara

Sponsors (1)

Lead Sponsor	Collaborator
Anemia Working Group Romania

Country where clinical trial is conducted

Romania, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	the composite event rate in death (any cause), myocardial infarction and stroke
Secondary	Cardio-vascular: the composite event rate of unstable angina, transient ischemic attacks, peripheral arterial disease, other, consequent to atherosclerosis
Secondary	Lipid profile